2022 World Conference on Lung Cancer (ePosters)-EP08.02-126. The MOMENT Disease Registry of Patients with Advanced Non-Small Cell Lung Cancer Harboring MET Exon 14 Skipping

EP08.02-126. The MOMENT Disease Registry of Patients with Advanced Non-Small Cell Lung Cancer Harboring MET Exon 14 Skipping

Back to course

Pdf Summary

The MOMENT disease registry is a non-interventional study collecting data on patients with advanced non-small cell lung cancer (NSCLC) who have MET exon 14 skipping and are receiving any systemic treatment. The registry aims to collect comprehensive and high-quality real-world clinical data to inform optimal care for this rare patient population. The data elements will be standardized according to recommendations from the European Medicines Agency (EMA), and data collection will continue for 5 years with an expected enrollment of approximately 700 patients.<br /><br />The registry will collect data from oncology and radiology sites in academic and community oncology settings, with 50 sites planned across Europe and North America. Eligible patients include those with advanced stage NSCLC and confirmed MET exon 14 skipping who are initiating or already receiving systemic therapy. The registry will assess effectiveness and safety outcomes, including tumor response, imaging data, mortality data, and adverse reactions.<br /><br />The MOMENT registry will also collect biomarker data, patient demographics, baseline clinical characteristics, and treatment details for each therapy line. The purpose of the registry is to generate real-world data for patients with MET exon 14 skipping NSCLC treated with systemic therapy, as limited data currently exists in this area. The data from the registry will be valuable for future research and studies in order to improve care for this rare patient population.<br /><br />Overall, the MOMENT registry aims to provide comprehensive and high-quality real-world data on the treatment and outcomes of patients with advanced NSCLC harboring MET exon 14 skipping. This data will be used to inform future research and improve care for this patient population.

Asset Subtitle

Petros Christopoulos

Meta Tag

Speaker Petros Christopoulos

Topic Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

Keywords

MOMENT disease registry

non-small cell lung cancer

MET exon 14 skipping

systemic treatment

real-world clinical data

European Medicines Agency

oncology and radiology sites

effectiveness and safety outcomes

biomarker data

treatment details